NASDAQ: SRDX
Surmodics Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their SRDX stock forecasts and price targets.

Forecast return on equity

Is SRDX forecast to generate an efficient return?

Company
3.7%
Industry
13.21%
Market
338.16%
SRDX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SRDX forecast to generate an efficient return on assets?

Company
2.5%
Industry
6.34%
SRDX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SRDX earnings per share forecast

What is SRDX's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.19
Avg 2 year Forecast
$0.29

SRDX revenue forecast

What is SRDX's revenue in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$124.1M+2.11%
Avg 2 year Forecast
$132.5M+9.02%
SRDX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SRDX revenue growth forecast

How is SRDX forecast to perform vs Medical Devices companies and vs the US market?

Company
4.41%
Industry
7.17%
Market
59.11%
SRDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SRDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SRDX vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
SRDX$27.50N/AN/A
CBLL$10.92$19.00+73.99%Strong Buy
TMCI$6.52$6.50-0.31%Hold
KIDS$16.58$25.00+50.78%Strong Buy
RXST$9.00$9.13+1.39%Hold

Surmodics Stock Forecast FAQ

What is SRDX's earnings growth forecast for 2026-2027?

(NASDAQ: SRDX) Surmodics's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 15.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.29%.

Surmodics's earnings in 2025 is -$19,863,000.On average, 4 Wall Street analysts forecast SRDX's earnings for 2026 to be -$2,785,497, with the lowest SRDX earnings forecast at -$3,672,052, and the highest SRDX earnings forecast at -$1,801,708.

In 2027, SRDX is forecast to generate $4,083,870 in earnings, with the lowest earnings forecast at $3,923,719 and the highest earnings forecast at $4,203,984.

If you're new to stock investing, here's how to buy Surmodics stock.

What is SRDX's revenue growth forecast for 2026-2027?

(NASDAQ: SRDX) Surmodics's forecast annual revenue growth rate of 4.41% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 59.11%.

Surmodics's revenue in 2025 is $121,575,000.On average, 4 Wall Street analysts forecast SRDX's revenue for 2026 to be $1,775,110,881, with the lowest SRDX revenue forecast at $1,687,170,395, and the highest SRDX revenue forecast at $1,846,893,197.

In 2027, SRDX is forecast to generate $1,895,224,716 in revenue, with the lowest revenue forecast at $1,820,868,532 and the highest revenue forecast at $1,950,848,860.

What is SRDX's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: SRDX) forecast ROA is 2.5%, which is lower than the forecast US Medical Devices industry average of 6.34%.

What is SRDX's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: SRDX) Surmodics's current Earnings Per Share (EPS) is -$1.40. On average, analysts forecast that SRDX's EPS will be -$0.19 for 2026, with the lowest EPS forecast at -$0.26, and the highest EPS forecast at -$0.13. In 2027, SRDX's EPS is forecast to hit $0.29 (min: $0.27, max: $0.29).

What is SRDX's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: SRDX) forecast ROE is 3.7%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.